These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 30657447)
1. Impact of naturally occurring variation in the human papillomavirus 52 capsid proteins on recognition by type-specific neutralising antibodies. Godi A; Bissett SL; Masloh S; Fleury M; Li S; Zhao Q; Xia N; Cocuzza CE; Beddows S J Gen Virol; 2019 Feb; 100(2):237-245. PubMed ID: 30657447 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes. Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963 [TBL] [Abstract][Full Text] [Related]
3. Impact of Naturally Occurring Variation in the Human Papillomavirus 58 Capsid Proteins on Recognition by Type-Specific Neutralizing Antibodies. Godi A; Martinelli M; Haque M; Li S; Zhao Q; Xia N; Cocuzza CE; Beddows S J Infect Dis; 2018 Oct; 218(10):1611-1621. PubMed ID: 29905865 [TBL] [Abstract][Full Text] [Related]
4. Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype. Bissett SL; Godi A; Fleury MJ; Touze A; Cocuzza C; Beddows S J Virol; 2015 Aug; 89(15):7748-57. PubMed ID: 25995264 [TBL] [Abstract][Full Text] [Related]
5. Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies. Godi A; Bissett SL; Miller E; Beddows S J Gen Virol; 2017 Jul; 98(7):1755-1761. PubMed ID: 28691664 [TBL] [Abstract][Full Text] [Related]
6. Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines. Godi A; Facchetti A; Bissett SL; Cocuzza C; Miller E; Beddows S J Virol; 2015 Dec; 90(6):3247-52. PubMed ID: 26719255 [TBL] [Abstract][Full Text] [Related]
7. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies. Godi A; Kemp TJ; Pinto LA; Beddows S J Infect Dis; 2019 Nov; 220(12):1940-1945. PubMed ID: 31412122 [TBL] [Abstract][Full Text] [Related]
8. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749 [TBL] [Abstract][Full Text] [Related]
9. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2. Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598 [TBL] [Abstract][Full Text] [Related]
10. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines. Ahmed AI; Bissett SL; Beddows S Infect Genet Evol; 2013 Aug; 18():151-9. PubMed ID: 23722024 [TBL] [Abstract][Full Text] [Related]
11. Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies. Godi A; Vaghadia S; Cocuzza C; Miller E; Beddows S Microbiol Spectr; 2022 Jun; 10(3):e0077922. PubMed ID: 35475682 [TBL] [Abstract][Full Text] [Related]
12. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies. Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978 [TBL] [Abstract][Full Text] [Related]
13. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908 [TBL] [Abstract][Full Text] [Related]
14. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency. Oumeslakht L; Ababou M; Badaoui B; Qmichou Z Gene; 2021 May; 782():145533. PubMed ID: 33636291 [TBL] [Abstract][Full Text] [Related]
16. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development. Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615 [TBL] [Abstract][Full Text] [Related]
17. Functional assessment and structural basis of antibody binding to human papillomavirus capsid. Zhang X; Li S; Modis Y; Li Z; Zhang J; Xia N; Zhao Q Rev Med Virol; 2016 Mar; 26(2):115-28. PubMed ID: 26676802 [TBL] [Abstract][Full Text] [Related]
18. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901 [TBL] [Abstract][Full Text] [Related]
19. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins. Bissett SL; Mattiuzzo G; Draper E; Godi A; Wilkinson DE; Minor P; Page M; Beddows S Vaccine; 2014 Nov; 32(48):6548-55. PubMed ID: 25203446 [TBL] [Abstract][Full Text] [Related]
20. Developments in L2-based human papillomavirus (HPV) vaccines. Schellenbacher C; Roden RBS; Kirnbauer R Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]